R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.